Source of material
The title compound was synthesized by hydrogenation of 7a-acetyl-6,14-e/uio-ethenotetrahydrothebaine, preparation was described previously [1] . This hydrogenation can be carried out at 40 °C and 10 atm pressure using a palladium catalyst. Under these conditions the reduction of the keto-group was not observed. A solution of the 7a-acetyl-6,14-ewdo-ethenotetrahydrothebaine (10 g) in ethanol (300 mL) was hydrogenated in the presence of palladium catalyst (3 g) at 40 °C and 10 atm for 8 hours. Removal of the catalyst by filtration followed by concentration of the solution under reduced pressure afforded the desired compound as a white crystalline solid (10 g). Recrystallization from ethanol gave crystals suitable for X-ray analysis (m.p. 132-134 °C).
Discussion
An increasing demand for medicinal opiates, coupled with a finite supply of natural products such as thebaine has created a special attention to this topic. Opioid analgesics represent one of the most important tools in a sequential approach to pain relief. Buprenorphine is a partial μ-opioid agonist developed as an agent for the treatment of opioid dependence [2] and possesses considerably affinity for both 8-and μ-opioid receptors [3] . These and other unique properties led us to synthesize buprenorphine from thebaine. In a multi-step synthesis of buprenorphine, the hydrogenation of 7a-acetyl-6,14-emfo-ethenotetra-hydrothebaine is a very important step in which we gained a series of crystals. The crystal structure determination revealed that the title compound is a polycyclic one with six rings. The molecule consists of a bicyclo[2. (9) 0(4) 
